Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-015-1470-z
Published Online: 2015-06-10
Published Print: 2015-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Carvajal, Richard D.
Schwartz, Gary K.
Mann, Helen
Smith, Ian
Nathan, Paul D.
License valid from 2015-06-10